Kernal Biologics
Summer 2020 · Active
Kernal is creating mRNA 2.0 therapies that work in specific cells
Location: Cambridge, MA, US
Team size: 20
About
Founders
Yusuf ErkulFounder
I'm co-founder and CEO of Kernal Biologics, a Cambridge, MA-based biotech startup developing next-generation messenger RNA immunotherapy. Backed by Hummingbird, Amgen, HBM, NASA, and Boeing, Kernal Bio raised more than $30M. Early in my career, I worked at Merck&Co. on the discovery and development of various oncology drugs, including ZEJULA®, which got FDA approval for ovarian cancer. I hold an executive MBA from MIT Sloan, an M.D. from Hacettepe Univ. and a B.S. in Biology from MIT.
Cafer OzdemirFounder
I got PhD in Molecular Genetics at UTSW Medical Center at Dallas. I moved to Boston for postdoctoral training at Harvard Medical School. I served as Biochemistry instructor at MIT. Then I joined Kernal as a co-founder.
Burak YILMAZFounder
My name is Burak Yilmaz, MS, co-founder, and lead designer of Kernal Biologics. As a synthetic biologist, I co-invented stealth and onco-selective mRNA platform technology in Kernal. Kernal is my second endeavor. Previously, I founded Sentegen/Sentebiolab which is a synthetic biology company that produces synthetic DNA for research and diagnostic purposes.